ASDA Partners With Avery Berkel and Hanshow to Enhance UK Sustainability and Supermarket Shopping Experience
25.7.2023 11:00:00 EEST | Business Wire | Press release
ASDA, in partnership with Avery Berkel and Hanshow, has launched a strategic project to create the first sustainability trial store in the UK that utilizes leading ESL technology and digital retail solutions to enhance operations and improve the shopping experience for customers. This partnership aims to promote refillable solutions for supermarket shopping in the UK, with a focus on sustainability and customer experience. Avery Berkel and Hanshow collaborated to leverage their expertise in retail scales, enterprise scale management, and electronic shelf labels (ESLs) to develop a sustainable solution for the Middleton store, eliminating the need for physical labels and creating a zero-waste solution for ASDA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230713235215/en/
Avery Berkel and Hanshow's solutions installed in ASDA (Photo: Business Wire)
The solutions offered by Avery Berkel and Hanshow allow ASDA to carry out its commitment to zero-waste shopping through its bring-your-own-container solution and promoting its ‘Refill Price Promise’ program, which guarantees lower prices to help customers shop more sustainably. ESL technology reduces the cost and time of manual updates, while allowing ASDA to make real-time changes to prices and promotions. It also allows customers to see price differences in wrapped and unwrapped versions of the same product. The solutions make it easier for customers to shop sustainably and are part of a greater effort to make ASDA’s refill areas more efficient and green.
Avery Berkel and Hanshow’s ESL technology streamlines in-store change administration and management, ensuring real-time price and product updates to keep shelves up to date and compliant with regulations. This flexibility to adjust prices and promotions enables retailers to respond promptly to market trends and customer demands, while reducing costs associated with label stock holding and consumables. Increased productivity and efficiency allow employees to focus on providing better customer service.
Customizability is another key feature of the ESL technology innovations, enabling ASDA and other retailers to incorporate custom fonts, images, logos, and graphics into the labels. This allows for brand alignment and a consistent visual identity across stores. The on-screen barcodes and QR codes facilitate easy scanning, streamlining checkout processes and enhancing operational efficiency.
The components of Avery Berkel and Hanshow’s solution are seamlessly integrated to provide shoppers with an enriching refill experience while emphasizing sustainability. Unlike standard printed shelf and product labels, the total refill solution offers additional product information such as refill instructions, ingredients, allergens, and storage details, encouraging sustainability in ASDA stores.
Avery Berkel and Hanshow aimed to revolutionize the shopping experience by making sustainable choices more accessible and engaging for customers. The shopper interface, designed to be simple and intuitive, ensures that even customers unfamiliar with this technology can easily navigate and participate. The collaboration among ASDA, Avery Berkel and Hanshow has led to a total solution that not only benefits the retail industry and its customers, but also provides a green solution and encourages more environmentally friendly retail practices and shopping habits. Consumer demand for sustainable retail will continue to grow in the future. Hanshow will strive to provide the sustainable retail solutions by continuously innovating and improving their digital labelling technology to meet the changing needs of customers and reduce environmental impact.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230713235215/en/
Contact information
Zishan Cai
zishan.cai@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom